(*) USA Approval Date: 2021. 10.13
+CT with or without bevacizumab
>Persistent PD-L1 (CPS ≥1)
Company
Generic Name: PembrolizuMAb
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 5
Patent>UpDate: 2019. 12.31.
RTM
RTM Web-Site